Elagolix sodium
| CAS No. | 832720-36-2 | Cat. No. | BCP16419 |
| Name | Elagolix sodium | ||
| Synonyms | NBI 56418Na;NBI-56418 sodium;NBI56418 sodium;NBI 56418 sodium;NBI56418Na; | ||
| Formula | C32H29F5N3NaO5 | M. Wt | 653.57 |
| Description | Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma. Elagolix was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued. | ||
| Pathways | GPCR/G Protein | ||
| Targets | GnRH Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.